The outcomes of a phase II, single-arm study involving patients with microsatellite-unstable (MSI) metastatic colorectal cancer receiving treatment with nivolumab reveal high levels of effectiveness. In a heavily pretreated population, 23 patients (31% of the cohort) had an objective response, while 51 (69%) had disease control for at least 12 weeks, after a median follow-up duration of 12 months. These data confirm the promise of previous studies involving immune-checkpoint inhibition in patients with MSI-positive solid tumours.
References
Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(17)30422-9 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. Nivolumab effective against MSI tumours. Nat Rev Clin Oncol 14, 586 (2017). https://doi.org/10.1038/nrclinonc.2017.132
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.132